The most successful trial to date in AML has been testing Aprea Therapeutics (APR)-246, a methylated, small-molecule derivative of PRIMA-1 (p53 re-activation and induction of massive apoptosis), which has been shown to bind and reactivate mutant and inactivated p53 by restoring its wild-type transcriptional activity to induce cell apoptosis [80,81]. Here, TP53 is linked to acute myeloid leukemia.